Druker, B J <br/><br/>
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.  [electronic resource] 

 -  The New England journal of medicine  Apr 2001 
 - 1031-7 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S. 
<br/><br/><label>ISSN: </label>0028-4793 
<br/><br/><label>Standard No.: </label>10.1056/NEJM200104053441401  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antineoplastic Agents--administration & dosage<br/>Benzamides<br/>Blood Cell Count<br/>Dose-Response Relationship, Drug<br/>Enzyme Inhibitors--administration & dosage<br/>Female<br/>Fusion Proteins, bcr-abl--antagonists & inhibitors<br/>Humans<br/>Imatinib Mesylate<br/>Interferon-alpha--therapeutic use<br/>Leukemia, Myelogenous, Chronic, BCR-ABL Positive--blood<br/>Male<br/>Middle Aged<br/>Phosphorylation<br/>Piperazines--administration & dosage<br/>Protein-Tyrosine Kinases--antagonists & inhibitors<br/>Pyrimidines--administration & dosage<br/>Recurrence<br/>Remission Induction--methods